Skip to main content

Day: April 11, 2023

Visualnet Media Inc. Becomes a Zerify Reseller and Adds Rosa & Co. LLC as a New Client

EDISON, N.J., April 11, 2023 (GLOBE NEWSWIRE) — Zerify Inc., (OTC PINK: ZRFY), the 22-year-old cybersecurity company focused on Secure Video Conferencing & Endpoint Security announced today that Visualnet Media has become a Zerify Reseller. Additionally, Visualnet Media is proud to welcome Rosa & CO. LLC as a new client, who will be using Zerify Meet to comply with compliance requirements. “Visualnet Media in one of the nation’s leading Security Hosting and IT Managed Service solution providers,” says Mark L. Kay, CEO of Zerify. “Their solution enables an entire corporate structure to be run remotely via their Secure Hosting facilities with the latest secure and compliant technology and solutions by custom tailoring each companies’ programs and needs with security always being baked into the infrastructure. Visualnet...

Continue reading

Dayton Children’s Hospital Bridges Epic Hyperdrive Migration with PortalGuard® IAM Cloud to Expand its Utilization of BIO-key Identity-Bound Biometrics

DAYTON, Ohio and WALL, N.J., April 11, 2023 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), announced that its longstanding customer Dayton Children’s Hospital will add BIO-key’s PortalGuard IDaaS® platform to expand its existing BIO-key biometric authentication investment as it migrates from Epic Systems’ legacy Hyperspace application to the new browser-based Hyperdrive end-user application interface. PortalGuard’s standards-based integration with Hyperdrive allows Dayton Children’s to continue enjoying BIO-key’s streamlined biometric authentication user experience for Epic security without re-enrollment or adoption of more cumbersome, shareable, and expensive multi-factor...

Continue reading

CODAN Communications Selects Draganfly’s UAV platform to Integrate as a Premium Communication Solution for Government and Defense Customers

Los Angeles, CA., April 11, 2023 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, is pleased to announce it has been selected by CODAN Communications (ASX:CDA), a leading international designer and manufacturer of premium communications solutions, to supply its UAV platform for integration with their industry-leading technology and communications solutions. CODAN Communications (Codan Limited ASX:CDA) serves tactical, military, humanitarian, peacekeeping, public safety, security, and commercial markets in over 150 countries. CODAN designs and deliver solutions that help to solve customers’ communications, safety, security, and productivity problems in some of the most challenging environments around...

Continue reading

CERIS’ “The Pulse of Payment Integrity” Outlines New Claims Processing Path For Payers

Strengthening Process Boosts Revenue, Improves Provider Relations FORT WORTH, Texas, April 11, 2023 (GLOBE NEWSWIRE) — CERIS, a CorVel company, has released “The Pulse of Payment Integrity,” a white paper encouraging healthcare payers to focus on reviewing claims before they are paid, as opposed to months or years afterward in a post pay environment. The whitepaper notes that taking such an approach to payment integrity reduces errors and improves the relationship between payers and providers by eliminating the need to collect excess payments after they have been made. New pressures on the existing healthcare payment process are also encouraging a move toward greater payment integrity. The white paper discusses issues created by the COVID-19 pandemic, which include the rapid introduction of telehealth services and increased difficulties...

Continue reading

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic leukemia and multiple myeloma Initial clinical data for LAVA-1207, a Phase 1/2a dose escalation clinical trial in patients with therapy refractory metastatic castration-resistant prostate cancer, suggest a favorable safety profile and initial signs of clinical activity, with PSA levels stabilizing or decreasing in highly pre-treated patients Announced license agreement with Seagen for the development of LAVA-1223 in exchange for $50 million upfront; up to approximately $650 million in potential milestones; and royalties Strong balance sheet with cash and investments of $132.9 million as of December 31, 2022, expected...

Continue reading

Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update

Annual revenue expected to exceed US$107 million for fiscal year ended March 31, 2023, an all-time record, including fiscal Q4 2023 revenue of at least US$28 million TORONTO and CHICAGO, April 11, 2023 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company’s fourth fiscal quarter and full fiscal year ended March 31, 2023, and, in addition, is providing an additional business update to shareholders and other stakeholders. All dollar amounts in this news release are in US dollars unless specified otherwise. Preliminary revenue estimates for fiscal year 2023 and fiscal Q4 2023 Medexus expects to deliver total revenue between $107 million and $108 million for fiscal year 2023, representing record annual revenue for Medexus and a year-over-year increase...

Continue reading

Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical Trial

Pivotal Phase 3 trial of MVA-BN® RSV has accrued enough cases required for efficacy analysis Topline results expected around mid-2023COPENHAGEN, Denmark, April 11, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Phase 3 clinical trial of MVA-BN® RSV, the Company’s investigational vaccine for the prevention of respiratory syncytial virus (RSV) in adults ≥60 years of age, has now accrued the number of cases required to complete the primary efficacy analysis, which is expected around mid-2023. Adjudicated data have confirmed enough cases with both 2+ symptoms and 3+ symptoms as required in the trial. The global, randomized, placebo-controlled, double-blind Phase 3 VANIR clinical trial has enrolled more than 20,000 participants across more than 100 centers in the U.S. and Germany. The primary objective of the study will...

Continue reading

Changes to KommuneKredit’s Board of Directors as of 1 April 2023

The election period for KommuneKredit’s Board of Directors follows the election period for municipal and regional councils staggered by 5 months. The current election period runs from 1 June 2022 to 31 May 2026. 6 board members are elected by the municipalities, 2 by the regions and 2 independent members – possessing qualifications within accounting, auditing, financial or risk management – are elected by the Board of Directors. As of 1 April 2023, the composition of the Board of Directors will change as follows: Martin Geertsen (Capital Region of Denmark) has resigned from the Board of Directors in accordance with KommuneKredits articles of association section 13 subsection 1 due to his resignation from the regional council. As of 1 April 2023, the regions have elected regional council member Carsten Scheibye, (Capital Region of Denmark)...

Continue reading

Emerging Markets Report: The Mastermind Behind the Brand

An Emerging Markets News Commentary ORLANDO, Fla., April 11, 2023 (GLOBE NEWSWIRE) — Previously, we introduced Kisses From Italy Inc. (OTCQB:KITL), a publicly listed U.S.-based company, restaurant chain operator, franchisor, and product distributor with locations in the United States, Canada and Europe, and its partnership with celebrity chef, Food Network Star, restaurateur and cookbook author Scott Conant. Now, it is time for the company’s current advisor, Fransmart, to have the spotlight. Fransmart is a global leader in franchise development, selling over 5,000 franchises worldwide and turning emerging restaurant concepts into national and global brands for 20 years. The company serves as Kisses From Italy’s current advisor and exclusive global developer and representative, aiding brand development and growth. Fransmart’s website...

Continue reading

Aravive Appoints Carolina Petrini as Chief Commercial Officer

HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Carolina Petrini as the Company’s new Chief Commercial Officer effective April 10, 2023. Ms. Petrini brings over two decades of experience in developing pre-commercial, launch readiness and commercial strategies, building and leading high-performing commercial teams. “We are delighted to welcome Carolina as our new Chief Commercial Officer,” said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. “With her extensive experience in oncology and exceptional track record of success in developing global commercial and launch strategies, we are confident that she will be a valuable asset to Aravive as...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.